Clinical trial

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

NCT06109402

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2023-12-20

PhasePHASE2

Study timeline

Study start (estimated)2023-12-20Date precision: day

Registry last updated2023-12-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Stage II-IIIB(N2) Non-small Cell Lung Cancerunresolved

Interventions

TQB2450DRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

PemetrexedDRUG · verified · RxNorm: pemetrexed

Nab-paclitaxelDRUG

SurgeryPROCEDURE

Sponsors & collaborators

Shanghai Pulmonary Hospital, Shanghai, Chinalead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06109402 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.